(Q35605046)

9 August 2017

1 reference

title

Nestorone: clinical applications for contraception and HRT. (English)

1 reference

9 August 2017

1 reference

Regine Sitruk-Ware

1

1 reference

9 August 2017

Margaret Small

2

1 reference

9 August 2017

Narender Kumar

3

1 reference

9 August 2017

Yun-Yen Tsong

4

1 reference

9 August 2017

Kalyan Sundaram

5

1 reference

9 August 2017

Theodore Jackanicz

6

1 reference

9 August 2017

publication date

1 November 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

68

1 reference

9 August 2017

issue

10-13

1 reference

9 August 2017

page(s)

907-913

1 reference

Nestorone: a progestin with a unique pharmacological profile

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

16-ALKYLATED PROGESTERONES

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Synthesis and biological activity of a new progestogen, 16-methylene-17alpha-hydroxy-18-methyl-19-norpregn-4-ene-3, 20-dione acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

The pharmacological profile of a novel norpregnance progestin (trimegestone).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

The Effect of Medroxyprogesterone Acetate on the Pituitary-Adrenal Axis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Androgenic, synandrogenic, and antiandrogenic actions of progestins

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Glucocorticoid properties of progestogens

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Potency and pharmacokinetics of gestagens

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Pharmacokinetics and bioavailability of ST 1435 administered by different routes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Pharmacokinetic observations on ST-1435 administered subcutaneously and intravaginally

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Vaginal rings for contraception in lactating women

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Vaginal rings delivering progesterone and estradiol may be a new method of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol andd-norgestrel

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Estradiol-delivering vaginal rings for hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Ovarian function during use of vaginal rings delivering three different doses of Nestorone

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Vaginal epithelial surface appearances in women using vaginal rings for contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

In VivoStudies on Progesterone Metabolism by Human Skin

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900140-5

7 January 2021

10.1016/S0039-128X(03)00140-5

Identifiers

DOI

1 reference

9 August 2017

1 reference